Meeting
2024 ASCO Genitourinary Cancers Symposium
Effect of cytoreductive nephrectomy on the efficacy of immunotherapy in metastatic renal cell carcinoma by decreasing IL-6 to modulate tumor-associated macrophage and myeloid-derived suppressor cell.
Authors
Jee Soo Park
Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea
Jee Soo Park , Myung Eun Lee , Won Sik Jang , Jongchan Kim , Gwangmo Shin , Won Sik Ham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 457)
DOI
10.1200/JCO.2024.42.4_suppl.457
Abstract #
457
Poster Bd #
J18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Efficacy of PD-1 inhibitors in the treatment of advanced gastrointestinal tumors and the effect on T-lymphocyte subsets and IL-6 levels in patients.
First Author: XinCheng He
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study.
First Author: Alessandra Anna Anna Prete
Poster
2020 ASCO Virtual Scientific Program
Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
First Author: Petri Bono
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna